Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | TOP1 | P11387 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1549275 | 0.91 | TRPV1 (0.43) | L3MBTL1ALDH1A1TRPV1GRM1MAPT | |
| SCHEMBL2348370 | 0.90 | TRPV1 (0.43) | L3MBTL1ALDH1A1TRPV1GRM1MAPT | |
| SCHEMBL2345220 | 0.90 | L3MBTL1 (0.55) | L3MBTL1ALDH1A1TRPV1GAAMAPT | |
| SCHEMBL1549272 | 0.90 | ALDH1A1 (0.43) | ALDH1A1TRPV1GRM1MAPTSMN1; SMN2 | |
| SCHEMBL2348926 | 0.89 | ALDH1A1 (0.43) | ALDH1A1TRPV1GRM1MAPTSMN1; SMN2 | |
| SCHEMBL2345187 | 0.89 | KDM4E (0.49) | L3MBTL1ALDH1A1TRPV1GRM1MAPT | |
| SCHEMBL2346049 | 0.89 | TRPV1 (0.52) | ALDH1A1TRPV1GRM1MAPTSMN1; SMN2 | |
| SCHEMBL2351476 | 0.89 | KDM4E (0.42) | L3MBTL1ALDH1A1TRPV1GRM1MAPT | |
| SCHEMBL1548738 | 0.88 | KDM4E (0.50) | L3MBTL1ALDH1A1GAAMAPTHTT | |
| SCHEMBL2349235 | 0.88 | TRPV1 (0.43) | ALDH1A1TRPV1GRM1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2314585-B1 | Condensed benzamide compounds as inhibitors of vanilloid receptor subtype 1 (VR1) activity | JAPAN TOBACCO INC (JP) | 2012-09-12 | — | — | EP | claimed |
| US-20060035882-A1 | CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY | JAPAN TOBACCO INC. (JP) | 2006-02-16 | — | — | US | claimed |
| US-8008292-B2 | Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity | JAPAN TOBACCO INC. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008292-B2 | Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity | JAPAN TOBACCO INC. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008292-B2 | Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity | JAPAN TOBACCO INC. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20060035882-A1 | CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY | JAPAN TOBACCO INC. (JP) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035882-A1 | CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY | TRPV1, TRPV2, TRPA1 | EGLN1 1937/4885L3MBTL1 3518/4885ALDH1A1 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.